In vivo selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing E. coli ST410

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Agnès B. Jousset, Delphine Girlich, Saoussen Oueslati, Aurélien Birer, Anne Delaval, Caroline Guyot, Inès Rezzoug, Cécile Emeraud, Thierry Naas, Rémy A. Bonnin, L Dortet
DOI: 10.1128/aac.01335-25
Cited by: 2
References: 24

Abstract

ABSTRACT Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing Escherichia coli ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.

Fields of Study & Subjects

Antibiotic Resistance in Bacteria Bacterial Identification and Susceptibility Testing Antibiotics Pharmacokinetics and Efficacy

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Volume
70
Issue
3
Pages
e0133525–e0133525
Publication date
12 February 2026
Language
EN